Physician profile
Ananda Som
NPI 1598739534
$3,681.45
in general payments reported to CMS, 2019-2025
26 companies · $142 in 2025
The $142 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $951 · 2020: $925 · 2021: $1,394 · 2022: $149 · 2023: $24.81 · 2024: $94.96 · 2025: $142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $262.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $262.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $787.23 | 2019-2024 | Lokelma |
| Glaxosmithkline, LLC. | $559.47 | 2019-2021 | |
| Novo Nordisk INC | $435.59 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $232.34 | 2019-2021 | |
| Abbvie INC. | $229.80 | 2021 | |
| Esperion Therapeutics, INC. | $178.40 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $177.46 | 2019-2022 | |
| Allergan, INC. | $161.52 | 2019-2021 | |
| Penumbra, INC. | $142.34 | 2025 | Indigo System |
| Janssen Pharmaceuticals, INC | $115.32 | 2020-2021 | |
| Astellas Pharma US INC | $109.84 | 2020-2021 | |
| Lilly USA, LLC | $107.63 | 2019-2021 | |
| Pfizer INC. | $79.70 | 2019-2021 | |
| Abiomed | $60.00 | 2019 | |
| Insmed, INC. | $39.82 | 2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $36.59 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $34.36 | 2021 | |
| Amgen INC. | $28.88 | 2020 | |
| Medtronic, INC. | $24.81 | 2023 | Intellis Adaptivestim |
| Bayer Healthcare Pharmaceuticals INC. | $23.57 | 2021 | |
| Dexcom, INC. | $23.27 | 2021 | |
| Merck Sharp & Dohme LLC | $22.03 | 2021 | |
| Nestle Healthcare Nutrition INC. | $21.40 | 2020 | |
| Medtronic Vascular, INC. | $18.83 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.47 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $12.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ananda Som listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.